NL
VRTX icon

NorthAvenue LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

NorthAvenue LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497 Hold
1
– – ﹤0.01% 269
2026
Q1 		$447 Hold
1
– – ﹤0.01% 237
2025
Q4 		$454 Buy
+1
New +$431 ﹤0.01% 280

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
SMDAM
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.5B AUM 37.68% 1-Year Est. Return

NorthAvenue LLC's VRTX Position: Q2 2026 in Review

NorthAvenue LLC held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1 share worth $497. The position accounts for ﹤0.01% of the portfolio, ranked #269.

NorthAvenue LLC first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 337 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • NorthAvenue LLC held 1 share of Vertex Pharmaceuticals worth $497 as of Q2 2026.
  • NorthAvenue LLC left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of NorthAvenue LLC's portfolio in Q2 2026, its #269 holding.
  • NorthAvenue LLC first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 337 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on NorthAvenue LLC's 13F filing for Q2 2026, filed 21 Jul 2026.